EP1169471A2 - Procede de criblage de composes au moyen de nematodes - Google Patents
Procede de criblage de composes au moyen de nematodesInfo
- Publication number
- EP1169471A2 EP1169471A2 EP00919099A EP00919099A EP1169471A2 EP 1169471 A2 EP1169471 A2 EP 1169471A2 EP 00919099 A EP00919099 A EP 00919099A EP 00919099 A EP00919099 A EP 00919099A EP 1169471 A2 EP1169471 A2 EP 1169471A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- nematode
- compound
- food source
- worms
- microorganism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 114
- 238000000034 method Methods 0.000 title claims abstract description 60
- 241000244206 Nematoda Species 0.000 title claims abstract description 57
- 238000012216 screening Methods 0.000 title claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 59
- 241000588724 Escherichia coli Species 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 17
- 239000001963 growth medium Substances 0.000 claims description 16
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 244000005700 microbiome Species 0.000 claims description 10
- 241001167795 Escherichia coli OP50 Species 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 239000003966 growth inhibitor Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 241000168726 Dictyostelium discoideum Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 14
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 48
- 229920001817 Agar Polymers 0.000 description 26
- 239000008272 agar Substances 0.000 description 25
- 241000894006 Bacteria Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 11
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 239000007844 bleaching agent Substances 0.000 description 6
- 230000010196 hermaphroditism Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000005499 meniscus Effects 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 244000144987 brood Species 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000012912 drug discovery process Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108010000700 Acetolactate synthase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000000504 luminescence detection Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
- 229960005457 pancuronium Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
- G01N2333/43526—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms
- G01N2333/4353—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes
- G01N2333/43534—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
Definitions
- the invention relates to the screening of compounds in the drug discovery process. More specifically, it relates to an improved method of compound screening using the nematode worm C. elegans .
- C. elegans is a nematode worm which occurs naturally in the soil but can easily be grown in the laboratory on nutrient agar seeded with a food source such as E. coli bacteria. Each worm grows from an embryo to an adult worm of about 1mm long in three days or so. As it is fully transparent at all stages of the life cycle, cell divisions, migrations and differentiation can be easily seen in live animals. Furthermore, although its anatomy is simple its somatic cells represent most major differentiated tissue types including muscle, neurons, intestine and epidermis. Accordingly, differences in phenotype which represent a departure from that of a wild-type worm are relatively easily observed, either directly by microscopy or by using selective staining procedures .
- C. elegans make it an extremely useful tool in the drug discovery process.
- C . elegans may be used in the development of high-throughput compound screens, useful in the identification of potential candidate drugs, in which worms are exposed to the compound under test and any resultant phenotypic and/cr behavioural changes are recorded.
- Such screening methods are critically dependent upon the ability to expose C. elegans to the compound under test. Usually this is achieved by culturing C. elegans in the presence of the compound so that the worms take up the compound.
- the standard method for culturing C. elegans in the presence of test compounds is described by Rand and Johnson in Methods in Cell Biology 48: 147-204. In this standard method, compounds are mixed with heated, liquid agar. After cooling to room temperature the plates are seeded with E . coli bacteria, the food source for the nematodes. The compound enters the nematode as it feeds on the bacteria and is thus able to perform its action.
- This standard method has the disadvantage that because the compound is mixed with the agar a comparatively large amount of compound is needed in order to perform the screen. Furthermore, compounds unstable at the temperature of liquid agar will loose their activity before the nematodes encounter them.
- the present inventors have developed a new screening method which requires much smaller amounts of compound and is more suitable for use in screening large compound libraries.
- the invention provides a method of compound screening in nematode worms, which method comprises the steps of:
- nematode encompasses nematodes of approximately the same size as C. elegans, being of the order 1mm long in the adult stage. Microscopic nematodes of this approximate size are extremely suited for use in mid- to high-throughput screening as they can easily be grown in the wells of a multi-well plate of the type generally used in the art to perform such screening.
- the nematode may be a wild-type strain or a non wild-type strain such as, for example, a mutated strain, a transgenic strain, or a mutant transgenic strain.
- Transgenic strains may carry transgenes encoding proteins of another species origin, e.g.
- the nematode may express a reporter gene such as, for example, lacZ, green fluorescent protein (including any of the variant GFPs and GFP equivalents known in the art) , luciferase, acetohydroxyacid synthase, alkaline phosphatase, ⁇ -glucuronidase, chloamphenicol acetyltransferase, horseradish peroxidase, nopaline synthase or octapine synthase in some or all cell types .
- a reporter gene such as, for example, lacZ, green fluorescent protein (including any of the variant GFPs and GFP equivalents known in the art) , luciferase, acetohydroxyacid synthase, alkaline phosphatase, ⁇ -glucuronidase, chloamphenicol acetyltransferase, horseradish peroxidase, nopaline synthase or octapine synthase
- nematode worms are grown on a solid growth medium which has been seeded with a nematode food source to which has been added a sample of a compound to be screened.
- the worms take up the compound as they feed on the food source.
- the method preferably uses E . coli as a food source for the nematodes but other food sources known for use with nematode worms could also be used. These include other bacterial species, yeasts and slime moulds (e.g. Dictyostelium discoideum) .
- the food source can be living organisms, dead organisms, synthetic food sources or extracts from living organisms.
- the food source can even be beads of any particular material on which nematodes such as C. elegans can feed.
- Suitable solid growth media include NGM agar which is routinely used for the culture of C. elegans in the laboratory. However, since it is no longer necessary to add the compound directly to the solid medium, as with the standard protocol described above, other polymer materials known to support growth of nematodes can be used. These polymer materials can be chosen in such a way that they give more or less adherence to the walls of microtiter plates.
- the method of the invention can be performed in various formats, including single small agar plates (e.g. 3.5 cm diameter) as well as microtiter plates (e.g. 12, 24, 96 and 384 well plates).
- agar plates e.g. 3.5 cm diameter
- microtiter plates e.g. 12, 24, 96 and 384 well plates
- additional problems have to be overcome, such as the formation of a meniscus by the agar.
- the problem of the formation of an optically distracting meniscus can be overcome with the use of microtiter plates manufactured or coated with a specific wall material. These plates, described as WIM plates for Without Interfering Meniscus, are provided by Swiss Aircraft and Systems Company. Other plates designed to prevent disturbing meniscus formation can also be used with equivalent effect.
- the polymer solution may be modified to achieve adhesive properties resulting in a decrease or absence of the optically distracting meniscus.
- Most of the other problems arising from using microtiter plates can be solved by applying microtiter plates in specific materials or coated with specific materials. It is an essential feature of the method of the invention that an amount of the compound to be tested is added to the nematode food source rather than to the solid growth medium. There are several different ways in which this can be achieved. In a first method a layer of food source is seeded onto the solid growth medium and an appropriate amount of the compound under test is then spread on top of the food source layer. For example, when E .
- coli is used as the food source 3.5cm diameter plates are seeded with a small drop (6 ⁇ l) of E . coli culture that grows to a small round lawn of about 4 mm diameter. Compounds dissolved in a suitable solvent e.g. DMSO are then put on top of the bacterial lawn to cover to lawn completely. In an alternative method, the compound can be mixed directly with the food source prior to seeding onto the solid growth medium.
- a suitable solvent e.g. DMSO
- the final concentration of compound added to the food source can be optimised by performing test screens with serial dilutions of the compound, as described the examples given herein.
- a final concentration of the compound should be chosen which is sufficient to have an effect on the worms but which does not cause any non-specific effects e.g. which is not lethal to the food source organisms to avoid worm starvation.
- care must also be taken to ensure that the final concentration of the solvent is kept low, typically below ⁇ 0.5% (equivalent to lO ⁇ l total volume of solvent per 2ml agar) . Higher concentrations of DMSO, especially more than 1%, are not tolerated well by C. elegans .
- any changes in the phenotype and/or behaviour of the worms following exposure to the compound can be readily observed over time under dissecting scopes, or any other method of visual detection.
- Other suitable detection methods which may be used to observe or measure changes in the phenotype and/or behaviour of the worms include light microscopy, differential interference contrast optics, fluorescence microscopy, immunological detection, radiation detection, calorimetric detection, fluorescence detection or luminescence detection.
- the worms are maintained in culture in the presence of the compound under test throughout several generations and observations of phenotype and behaviour of the worms are made at regular intervals of time over the successive generations.
- the brood of one single L4 hermaphrodite worm is grov/n up to adulthood under the permanent influence of a test compound.
- Other compound screens may be performed by plating several worms and observing the effects of test compounds on the parental generation only, on a shorter timescale.
- the compounds to be tested using the screening method of the invention may be any chemical substance, including natural substances, extracts isolated from natural substances, compounds isolated from natural substances, compounds from combinatorial libraries or selected compounds or drugs from the pharmacopoeia.
- the compounds can be proteins, peptides or nucleic acids, for example double-stranded DNA, single- stranded DNA, single-stranded or double-stranded RNA.
- the DNA, RNA, protein or peptide can be added to the bacteria layer or, in an alternative embodiment, can be produced by the food source organisms themselves.
- the compound to be screened is added to the food source rather than to the solid growth medium. It is therefore important to ensure that the nematodes are prevented from feeding on any food source which does not contain the compound to be tested, since this would decrease the overall value of the screening method.
- worms feeding on the food source repeatedly move in to and out of the food source layer.
- the worms are able to spread some of the food source organisms outside of the area originally contacted with the food source/compound (hereinafter referred to as the 'contact area') by leaving them with their tracks. Diffusion of the compound outside of the original contact area is often found to be limited, in which case any food source organisms able to grow outside the contact area will contain the compound at a much reduced concentration. If this is allowed to occur the worms will preferentially feed on the food source organisms growing outside the original contact area and hence avoid uptake of the compound under test.
- the applied compound frequently forms a kind of film on the food source.
- the food source is able to grow beneath, where it has food supplies from the nutrient rich agar.
- the film with the compound is then lifted and the nematodes can feed on the fresh food source, without or with less feeding on the food source containing the compound.
- the possibility that the worms are able to feed on food source which does not contain any of the compound under test or contains the compound at a very low concentration will obviously tend to decrease the value and general application of the compound screening method. Accordingly, it is an essential part of the method of the invention that the nematodes are prevented from feeding on any food source organisms which do not contain the compound under test.
- the present inventors have developed several ways of overcoming this problem.
- the problem is overcome by limiting the growth of the food source organisms under the conditions of the compound screening assay. This can be accomplished by adding growth inhibitor substances to the food source and/or the solid growth medium in order to prevent further growth of the food source organisms.
- Suitable growth inhibitors are antibiotics such as, for example, carbenicillin, tetracycline or kanamycin.
- the food source can be inhibited in replication by irradiation either prior to applying it to the solid growth medium, or after it has been applied to the solid growth medium.
- growth of the food source organisms can be controlled during the course of the screening assay by using cold-sensitive organisms as the food source. Cold- sensitive bacteria are preferred for use in this embodiment but cold-sensitive variants of other types of food source organisms could also be used.
- E . coli strains that show reduced growth under the conditions used for the culture of nematode worms (typically a few days at 20°C, but other conditions of growth may be selected) .
- bacterial strains are selected that grow only a very limited amount at this temperature. In this circumstance, the growth of the cold-sensitive bacteria outside the original contact area is extremely limited and is not enough to support feeding of the nematode. This ensures that the worms feed only on those bacteria that have been soaked with compound, in the meanwhile taking up compounds while feeding on these bacteria.
- Suitable cold-sensitive bacterial strains for use in this embodiment of the invention include E .
- cold-sensitive variants of E. coli strain OP50 which is commonly used as a food source for the culture of C. elegans , can be constructed using standard mutagenesis and selection techniques known in the art ( E. coli strain OP50 can be obtained from the C. elegans Genetics Center, University of Minnesota, St Paul, Minnesota, USA) .
- E. coli strain OP50 can be obtained from the C. elegans Genetics Center, University of Minnesota, St Paul, Minnesota, USA
- coli strain OP50 are mutagenized using a standard mutagenesis technique such as EMS (ethyl methane sulfonate mutagenesis, described in "Methods in Cell Biology, Vol 48 page 31-35”) .
- EMS ethyl methane sulfonate mutagenesis, described in "Methods in Cell Biology, Vol 48 page 31-35”
- a large number of colonies of mutagenized bacteria (approximately 3000) are then patched onto duplicate agar plates. One plate is grown at 20°C, while the other plate is grown at 37°C. Colonies grown at 37°C of which the sister colony at 20°C showed no or very little growth are then re-tested at both temperatures. Following this procedure the inventors were able to isolate 5 colonies that showed strongly reduced growth at 20°C.
- the cold sensitive strains derived from E . coli strain OP50 grow a little slower than OP50 at 37°C.
- Example 1-screening compounds from a combinatorial library 248 individual compounds from a combinatorial library were tested on wild-type C. elegans .
- NGM agar nematode growth medium
- NGM agar nematode growth medium
- 15g agar Agar SERVA high gel strength, Nr. 11396
- lg peptone Difco Bacto Peptone, Nr. 0118
- 3g NaCl 1 ml cholesterol solution (5 mg/ml in EtOH)with sterile addition after autoclaving of: 9.5 ml 0.1 M CaCl 2 9.5 ml 0.1 M MgS0 4 , 25ml 1M
- the plates were seeded with 6 ⁇ l of E . coli OP50cs2 overnight culture. Overnight cultures of OP50cs2 typically grow to OD 0.47. If necessary, depending on the food demand of the worms and/or the size of the plates used for the assay, the overnight culture can be concentrated by centrifugation to OD -0.95. The bacteria are left to grow for one week at room temperature to form a thin lawn. lO ⁇ l of compound in DMSO is then pipetted on top of the bacterial lawn to cover the lawn completely. The solution is allowed to soak in for a few hours or overnight.
- the DMSO dilutes completely in the agar, resulting in a final concentration of 0.5% if lOul were pipetted on 2ml agar. It is preferably not to exceed this concentration, as higher concentrations of DMSO, especially more than 1%, are not well tolerated by C. elegans .
- One L4 hermaphrodite worm per plate is placed onto the bacterial lawn, at the same time taking care not to transfer any non-cold-sensitive bacteria onto the screening plate.
- the plates are then incubated at 21°C to allow the brood of the single L4 hermaphrodite worm to grow up to adulthood and are checked at regular intervals of time to identify any changes in phenotype and/or behaviour. By doing this a whole generation of worms grown under the permanent influence of the compound can be scored for changes in phenotype and/or behaviour.
- several hermaphrodite worms could be plated onto the same__-bacterial lawn in order to observe effects of the compound on the parental generation only. In this case the timescale of the assay can be shortened accordingly.
- the plates are then seeded with a lawn of E. coli OP50 according to the standard protocol, taking care to add sufficient food source bacteria to allow the brood of the single hermaphrodite worm to grow up to adulthood.
- One L4 hermaphrodite worm per plate is put onto the bacterial lawn and the plates incubated at 21°C. The plates are checked at regular intervals of time for any changes in phenotype and/or behaviour. Each dilution of compound was tested in triplicate.
- Results A comparison was made between the results obtained using the method of the invention, using cold- sensitive bacteria in this instance, and the standard method known from the literature. For the majority of compounds the method of the invention was found to be more efficient than the standard method. Table 2 lists the calculated concentration ratio needed to get the same effect with the compound using the standard method (in 2ml agar) as compared to the method of the invention (on 4ml agar) for all the compounds that showed a comparable effect in both screening methods. For one of the compounds tested, pancuronium, no effect was observed using 1.66mg of compound in the highest concentration of the standard assay whilst there was an observable effect on the phenotype of the worms using 0.033mg (and O.lmg) in the method of the invention.
- the method of the invention enables the identification of effects of compounds that could not have been identified using the standard screening method known in the art.
- Using the new method it is possible to screen a compound library using -O.lmg of compound, whereas using the standard method ⁇ 2mg would be needed per concentration series (assuming a molecular weight of 500) .
- This represents a clear advantage in using the new method since very often such large amounts of compound are not available, particularly when the compound is a newly synthesised compound or a compound from a combinatorial library.
- the plates are examined random for cracks at delivery and during storage.
- One plate of the batch is seeded with E.coli OP50 _rcs2 grown for one week. 10 ⁇ L DMSO is added to six of the wells.
- Plates are seeded one week before use minimum three weeks before use maximum.
- the bacterial strain used is streaked from an -80°C glycerol stock (provided with a batch number) on a TY-plate. This plate is grown overnight at 37°C and stored at 20°C for four weeks maximum. 1. Seed 50 ml of LB with a colony of OP50 cs2 and let grow overnight at 37 °C in a shaker. 2. Measure optical density at 600 nm of a lOx diluted culture, using LB as blank. Calculate which dilution you have to make to have an O.D. of 1.4-1.5. Make this dilution and use it to seed the plates 3. Put 10 ⁇ L drops of the diluted OP50 cs2 culture in the middle of the well if using 12 well plates and 5 ⁇ l if using 24 well plates. A Robot such as a Tecan robot can be used for seeding 12 well plates.
- Plates with bacteria can be stored at 10°C for three weeks.
- Day 0 is the day of dispensing and profiling:
- Day -8 Grow at 15°C nematodes obtained from stock plates containing many dauer larvae by transferring pieces of agar to fresh 9cm plates containing a lawn of E . coli OP50 as food.
- Day -4 Bleach the nematodes collected from the 10 plates and dispense the eggs on 20 fresh plates seeded with E . coli OP50cs2.
- the nematodes need to be grown on the same bacterial strain that is loaded with compound in the microwell plate.
- Each 9cm plate should give enough young adult worms to fill 2 12-well plates with 20 worms per well so this would be enough for 40 12-well plates . 2.
- Half the plates can be used to bleach again to stage worms for a second day of profiling in the week, but bleach only two times in row maximum because of possible mutations due to the bleach procedure.
- Day -1 Check the stage of the worms from the bleach to be able to put them on a higher temperature to reach the young adult stage in time.
- worm dispenser apparatus e.g. the device commercially available from Union Biometrica, Inc, Somerville, MA, USA which has properties analogous to flow cytometers, such as fluorescence activated cell scanning and sorting devices (FACS)).
- FACS fluorescence activated cell scanning and sorting devices
- Use appropriate profile (12 or 24 well) for the fastest dispensing obtain a flow-rate of 15-20 events per second.
- Compounds are prepared and put on the plates one day in advance. Prepare stock-solutions and two dilutions of the compounds tested; the default concentration of the stock solution is lOOmM in 90 ⁇ L of the appropriate solvent. The two dilutions are by default 10 mM and 1 mM in ..the appropriate solvent. If a compound does not dissolve, recover the powder by vacuum extraction and use another solvent like acetone or DMSO. Test the tendency of a compound to form a crust or crystals by pipetting 5 ⁇ l of the solution onto a test plate with OP50 . If a crust is observed further diluting of the compound is recommended.
- DMSO and 5 ⁇ l of both solutions is added into separate wells of a 24 well plate containing NGM medium and a spot of OP50 cs2 bacteria.
- the 24 well plate will then have the following layout:
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Cette invention concerne des procédés améliorés de criblage de composés présentant une activité pharmacologique potentielle au moyen de nématodes, principalement, mais pas exclusivement de C. elegans. L'invention concerne en particulier des procédés selon lesquels le composé testé est ajouté directement à un organisme dont se nourrit directement un nématode et absorbé par ce dernier.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9908676 | 1999-04-15 | ||
GBGB9908676.1A GB9908676D0 (en) | 1999-04-15 | 1999-04-15 | Method for screening compounds |
PCT/IB2000/000554 WO2000063424A2 (fr) | 1999-04-15 | 2000-04-14 | Procede de criblage de composes au moyen de nematodes |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1169471A2 true EP1169471A2 (fr) | 2002-01-09 |
Family
ID=10851618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00919099A Withdrawn EP1169471A2 (fr) | 1999-04-15 | 2000-04-14 | Procede de criblage de composes au moyen de nematodes |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1169471A2 (fr) |
JP (1) | JP2002542464A (fr) |
AU (1) | AU3984400A (fr) |
CA (1) | CA2369734A1 (fr) |
GB (2) | GB9908676D0 (fr) |
HK (1) | HK1030450A1 (fr) |
WO (1) | WO2000063424A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1732379B1 (fr) | 2004-04-09 | 2013-11-06 | Monsanto Technology LLC | Compositions et procédés pour le contrôle des invasions d'insectes sur les plantes |
KR100848790B1 (ko) * | 2006-12-27 | 2008-07-30 | 연세대학교 산학협력단 | 소나무 재선충, 다이플로스캡터 및 예쁜 꼬마선충에 대한살선충제의 고속 스크리닝 방법 |
US10514375B2 (en) * | 2015-01-23 | 2019-12-24 | Bayer Aktiengesellschaft | Device and method for determining the action of active ingredients on nematodes and other organisms in aqueous tests |
CN114794029B (zh) * | 2022-06-09 | 2023-02-28 | 上海大学 | 一种计数秀丽隐杆线虫子宫内发育胚胎数目的方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55153599A (en) * | 1979-05-18 | 1980-11-29 | Duskin Franchise Co Ltd | Toxic test method of chemical substance by using nematode |
WO1990009096A2 (fr) * | 1989-02-03 | 1990-08-23 | Cambridge Neuroscience Research, Inc. | Procede de tirage et de classification de composes |
AU752962B2 (en) * | 1997-05-15 | 2002-10-03 | General Hospital Corporation, The | Therapeutic and diagnostic tools for impaired glucose tolerance conditions |
US6329566B1 (en) * | 1997-05-29 | 2001-12-11 | The General Hospital Corporation | Methods for the detection, treatment, and prevention of neurodegeneration |
GB9826890D0 (en) * | 1998-12-07 | 1999-01-27 | Devgen Nv | Method for screening compounds |
-
1999
- 1999-04-15 GB GBGB9908676.1A patent/GB9908676D0/en not_active Ceased
-
2000
- 2000-04-14 GB GB0009364A patent/GB2350896B/en not_active Expired - Fee Related
- 2000-04-14 WO PCT/IB2000/000554 patent/WO2000063424A2/fr not_active Application Discontinuation
- 2000-04-14 JP JP2000612501A patent/JP2002542464A/ja active Pending
- 2000-04-14 AU AU39844/00A patent/AU3984400A/en not_active Abandoned
- 2000-04-14 EP EP00919099A patent/EP1169471A2/fr not_active Withdrawn
- 2000-04-14 CA CA002369734A patent/CA2369734A1/fr not_active Abandoned
-
2001
- 2001-02-05 HK HK01100798A patent/HK1030450A1/xx not_active IP Right Cessation
Non-Patent Citations (2)
Title |
---|
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, May 1996 (1996-05-01), pages 4857 - 4861 * |
See also references of WO0063424A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000063424A3 (fr) | 2001-02-08 |
GB2350896B (en) | 2001-04-25 |
GB2350896A (en) | 2000-12-13 |
GB0009364D0 (en) | 2000-05-31 |
WO2000063424A2 (fr) | 2000-10-26 |
HK1030450A1 (en) | 2001-05-04 |
AU3984400A (en) | 2000-11-02 |
JP2002542464A (ja) | 2002-12-10 |
GB9908676D0 (en) | 1999-06-09 |
CA2369734A1 (fr) | 2000-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Aranda-Díaz et al. | Bacterial interspecies interactions modulate pH-mediated antibiotic tolerance | |
Hodgkin et al. | Genetics of gliding motility in Myxococcus xanthus (Myxobacterales): genes controlling movement of single cells | |
Lilly et al. | smellblind: a gene required for Drosophila olfaction. | |
DE60307645T2 (de) | Hoch-durchsatz assay zur messung von zellulären antworten mit hilfe von mikroarrays | |
Harte et al. | Genetic analysis of mutations at the Glued locus and interacting loci in Drosophila melanogaster | |
US6664441B1 (en) | Compound assay | |
Christensen et al. | Vibrio fischeri: laboratory cultivation, storage, and common phenotypic assays | |
JP2002542466A (ja) | 化合物スクリーニング法 | |
Squiban et al. | C. elegans: an all in one model for antimicrobial drug discovery | |
DEE | Genetics of Physarum polycephalum | |
Gong et al. | Competitive interactions between incompatible mutants of the social bacterium Myxococcus xanthus DK1622 | |
WO2000063424A2 (fr) | Procede de criblage de composes au moyen de nematodes | |
JP2004500866A (ja) | C.elegansの成長期依存発現に基づくアッセイ技法 | |
Forsburg | Growth and manipulation of S. pombe | |
Vaksman et al. | Myxococcus xanthus growth, development, and isolation | |
Aranda-Díaz et al. | Bacterial interspecies interactions modulate pH-mediated antibiotic tolerance in a model gut microbiota | |
US20060288429A1 (en) | Genetic screen in drosophila for metastatic behavior | |
Medvedik et al. | Caloric restriction and life span determination of yeast cells | |
WO2022071239A1 (fr) | Procédé d'évaluation d'une plaque et procédé d'évaluation de la toxicité d'un échantillon | |
Popiel et al. | Generation and analysis of CCM phenotypes in C. elegans | |
Theurkauf et al. | Identification and characterization of mitotic mutations in Drosophila | |
Schøler et al. | Isolating genes involved with genotoxic drug response in the nematode Caenorhabditis elegans using genome-wide RNAi screening | |
Arjes et al. | Three-dimensional biofilm growth supports a mutualism involving matrix and nutrient sharing | |
Aranda-Díaz | Probing Gut Bacterial Physiology and Antibiotic Action in Complex Environments | |
JP4323844B2 (ja) | バイオアッセイ装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011109 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DEVGEN NV |
|
17Q | First examination report despatched |
Effective date: 20041114 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050426 |